loading page

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
  • +3
  • Leona Dold,
  • Philipp Lutz,
  • Annkristin Heine,
  • Tobias Weismüller,
  • Christian Strassburg,
  • Ulrich Spengler
Leona Dold
Author Profile
Philipp Lutz
University Hospital Bonn
Author Profile
Annkristin Heine
University Hospital Bonn
Author Profile
Tobias Weismüller
University Hospital Bonn
Author Profile
Christian Strassburg
University Hospital Bonn
Author Profile
Ulrich Spengler
University Hospital Bonn
Author Profile

Abstract

Patients after liver transplantation have an increased risk to develop haematologic neoplasias. Information how to treat these patients in the context of immunosuppression is sparse. Here, we report two patients with polycythemia vera (PV) and myelofibrosis (MF) on ruxolitinib after liver transplantation.

Peer review status:IN REVISION

19 Jan 2021Submitted to Clinical Case Reports
21 Jan 2021Assigned to Editor
21 Jan 2021Submission Checks Completed
08 May 2021Reviewer(s) Assigned
22 May 2021Review(s) Completed, Editorial Evaluation Pending
24 May 2021Editorial Decision: Revise Minor